Grifols stock: Q3 cash flow strengthens debt-reduction case
Published on 11/06/2026 at 17:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCash flow and debt shape outlook
- Third-quarter growth was led by Biopharma and immunoglobulin demand.
- Lower leverage and refinancing extended the company's financial flexibility.
- Albumin weakness in China and the SPARTA study remain important catalysts.
Grifols reported stronger third-quarter operating momentum on November 2, 2026, with higher revenue, profit and cash generation. The latest AD HOC NEWS report, citing Yahoo Finance, said management left its full-year guidance unchanged despite pressure in China.
Grifols stock traded at 11.25 euros on Lang & Schwarz at 17:38:10 CET on Friday, November 6, 2026. Investors can track the real-time quote of Grifols stock.
Biopharma leads quarterly growth
Third-quarter revenue reached 2.04 billion euros, an 8.4 percent increase at constant currency and above the 1.98 billion euro consensus estimate. Net profit rose 27.9 percent to 162 million euros, while adjusted EBITDA increased 9.8 percent at constant currency to 538 million euros. The adjusted EBITDA margin reached 26.4 percent.
Biopharma revenue increased 10.3 percent at constant currency. Immunoglobulin sales rose 11.3 percent, and subcutaneous immunoglobulin advanced 40.3 percent. The Alpha-1 and specialty proteins franchise grew 18.2 percent.
The portfolio remained uneven. Albumin revenue declined 13.2 percent as regulatory factors and elevated inventories in China weighed on demand. That weakness remains a risk because it offsets part of the momentum in higher-growth franchises.
Cash generation reduces debt pressure
Free cash flow before mergers and acquisitions reached 208 million euros in the quarter. Net leverage fell to 3.98 times from 4.2 times a year earlier, while liquidity increased to 2.14 billion euros. Grifols also refinanced obligations due in 2027, leaving no significant maturities until the fourth quarter of 2028.
Management continues to target a 25 percent adjusted EBITDA margin for the full year. The next operating test is whether cash generation can continue to reduce leverage while China albumin demand remains weak. Investors are also awaiting topline results from the Phase 3 SPARTA study, expected by the end of the fourth quarter.
Grifols at a glance
- Company: Grifols S.A.
- ISIN: ES0171996087
- Latest Lang & Schwarz quote: 11.25 euros at 17:38:10 CET on Friday, November 6, 2026
- Third-quarter revenue: 2.04 billion euros
- Adjusted EBITDA: 538 million euros with a 26.4 percent margin
- Net leverage: 3.98 times
Broader Spanish equity sentiment remains relevant for healthcare shares. See current IBEX 35 market reports for the wider market environment.
